APIs and Excipients

Pharmaceutical Technology's In the Lab eNewsletter

Antibody Development Made Easier with Synthetic Biology

February 05, 2020

Synthetic biology can help researchers circumvent the challenges of traditional methods of antibody generation.

The Search for Transparency in Excipient Sourcing

February 02, 2020

Researching excipient grades and sources, as well as screening suppliers and materials, form the basis of programs to mitigate risk.

Daiichi Sankyo Licenses ERS Genomics’ CRISPR Gene Editing Tech

January 31, 2020

Pharmaceutical Technology's In the Lab eNewsletter

The license gives Daiichi Sankyo access to ERS Genomics’ genome-editing technology for internal R&D initiatives.

Otsuka, PhoreMost Team Up for Drug Discovery

January 31, 2020

Pharmaceutical Technology's In the Lab eNewsletter

Otsuka will use PhoreMost’s phenotypic screening platform to identify new targets for drug development, with a focus on gene therapy.

WuXi Biologics, Almirall Partner to Develop Bispecific Antibodies for Skin Diseases

January 09, 2020

Under the agreement, Almirall will leverage WuXi Biologics’ proprietary WuXiBody platform to develop bispecific antibodies for dermatological diseases.

ProBioGen Inks Commercial GlymaxX Deal with Roche

January 08, 2020

Roche will apply ProBioGen’s proprietary GlymaxX technology to boost the antibody-dependent cellular cytotoxicity activity of antibodies.

Polyplus-transfection Expands GMP Portfolio for Gene and Cell Therapy Manufacturing

January 06, 2020

Pharmaceutical Technology's In the Lab eNewsletter

The new GMP conditioning product offering is designed to support clinical phase and commercialization stages of cell and gene therapy production.